Advanced Health Intelligence Ltd Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 345.76M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Advanced Health Intelligence Ltd operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, fitness and wellness, and consumer apparel sectors. The company was formerly known as MyFiziq Limited and changed its name to Advanced Human Imaging Limited in March 2021. Advanced Human Imaging Limited was incorporated in 2014 and is based in South Perth, Australia.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks